- Home
- VLTO vs BIIB Comparison
VLTO vs BIIB Comparison
Compare VLTO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLTO
- BIIB
- Stock Information
- Founded
- VLTO 2023
- BIIB 1978
- Country
- VLTO United States
- BIIB United States
- Employees
- VLTO N/A
- BIIB N/A
- Industry
- VLTO Electrical Products
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- VLTO Industrials
- BIIB Health Care
- Exchange
- VLTO Nasdaq
- BIIB Nasdaq
- Market Cap
- VLTO 26.5B
- BIIB 18.7B
- IPO Year
- VLTO N/A
- BIIB 1991
- Fundamental
- Price
- VLTO $107.82
- BIIB $143.32
- Analyst Decision
- VLTO Buy
- BIIB Buy
- Analyst Count
- VLTO 7
- BIIB 27
- Target Price
- VLTO $114.00
- BIIB $188.09
- AVG Volume (30 Days)
- VLTO 908.6K
- BIIB 1.5M
- Earning Date
- VLTO 10-22-2025
- BIIB 10-29-2025
- Dividend Yield
- VLTO 0.41%
- BIIB N/A
- EPS Growth
- VLTO 12.21
- BIIB 31.67
- EPS
- VLTO 3.58
- BIIB 10.45
- Revenue
- VLTO $5,362,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- VLTO $8.01
- BIIB $2.00
- Revenue Next Year
- VLTO $5.46
- BIIB N/A
- P/E Ratio
- VLTO $30.23
- BIIB $13.78
- Revenue Growth
- VLTO 5.61
- BIIB 3.36
- 52 Week Low
- VLTO $83.87
- BIIB $110.04
- 52 Week High
- VLTO $115.00
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- VLTO 54.37
- BIIB 57.98
- Support Level
- VLTO $104.76
- BIIB $139.54
- Resistance Level
- VLTO $109.86
- BIIB $150.28
- Average True Range (ATR)
- VLTO 1.55
- BIIB 4.43
- MACD
- VLTO 0.07
- BIIB 0.47
- Stochastic Oscillator
- VLTO 65.19
- BIIB 62.90
About VLTO Veralto Corp
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.